Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

PURPOSE: The primary aim of this trial was to assess the rate of pathologic complete responses (pCR) of doxorubicin/cyclophosphamide (AC) followed by bevacizumab/docetaxel (BT), as neoadjuvant therapy for breast cancer (BC). Furthermore, the association between biomarkers and the pCR was explored. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Rovira, P., Seguí, M. A., Llombart, A., Aranda, E., Antón, A., Sánchez, A., Lomas, M., Jaén, A., Fernández, M., Porras, I., Dalmau, E., Morales, S., de la Haba-Rodríguez, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776259/
https://www.ncbi.nlm.nih.gov/pubmed/23397155
http://dx.doi.org/10.1007/s12094-013-1006-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776259/
https://www.ncbi.nlm.nih.gov/pubmed/23397155
http://dx.doi.org/10.1007/s12094-013-1006-4

Ejemplares similares